ÃÛÌÒÊÓÆµ

Life Sciences

  • September 12, 2025

    Jury Awards Mallinckrodt $9.5M In Nitric Oxide Patent Suit

    A Delaware federal jury awarded Mallinckrodt Pharmaceuticals almost $9.5 million on Friday, finding that French industrial gas company Airgas Healthcare infringed patents covering its inhaled nitric oxide treatment.

  • September 12, 2025

    Novartis Takes Entresto Bench Trial Loss To Fed. Circ.

    Novartis urged the Federal Circuit on Friday to save it from a Delaware federal judge's holding that generic-drug maker MSN Pharmaceuticals did not infringe a patent covering the blockbuster cardiovascular drug Entresto.

  • September 12, 2025

    US Sprinter Gets 4-Year Doping Ban Despite Oxtail Defense

    The international Court of Arbitration for Sport on Friday imposed a four-year suspension on American track and field star Erriyon Knighton, who earned medals in two World Championships and competed in the 2021 and 2024 Summer Olympics in the 200 meters, rejecting his explanation blaming the test result on tainted oxtails.

  • September 12, 2025

    Saudi Blockade Leads To $100M Award To Qatar Pharma Co.

    A Qatari pharmaceutical distributor and its chairman were awarded nearly $100 million in arbitration against Saudi Arabia after its business in the country was left "in shambles" due to a 2017 anti-terrorism blockade, though annulment proceedings in England remain ongoing, according to a newly removed lawsuit.

  • September 12, 2025

    Boehringer Misused Forfeited Retirement Funds, Suit Says

    Pharmaceutical giant Boehringer Ingelheim cost workers millions of dollars by using forfeited retirement plan funds to cover company contributions rather than administrative fees charged to participants, according to a proposed class action filed in Connecticut federal court.

  • September 12, 2025

    Ex-Conn. Assistant AG Faces DQ Bid In Price-Fixing Case

    Drug companies accused of fixing prices for generics are seeking to disqualify former Connecticut Assistant Attorney General Joseph Nielsen and his law firm from representing insurers in a multidistrict litigation, arguing Nielsen had access to confidential information as a government attorney that he could unfairly use against them now.

  • September 12, 2025

    UK Litigation Roundup: Here's What You Missed In London

    This past week in London has seen former Master Chef presenter Gregg Wallace sue the BBC, Elon Musk's xAI take legal action against a staff engineer, and fashion mogul Kevin-Gerald Stanford file a fresh claim against Lion Capital-owned Klotho and EY amid a long-running All Saints share acquisition dispute.

  • September 11, 2025

    States Push Conn. Court To Ban Generic Drug Price-Fixing

    A court order is necessary to prevent pharmaceutical companies and their executives from illegally fixing the prices of generic drugs, a coalition of state enforcers have told a Connecticut federal judge, arguing there is a "reasonable expectation" that the allegedly anticompetitive behavior at the center of multidistrict litigation will happen again.

  • September 11, 2025

    9th Circ. Says News Article Doesn't Doom Biotronik FCA Suit

    The Ninth Circuit revived a False Claims Act suit alleging that Biotronik orchestrated an illicit compensation scheme to boost the implantation of its cardiac devices in patients at Cedars-Sinai Medical Center in Los Angeles, saying the whistleblower's complaint presents new information that is not barred by fraud allegations disclosed in an earlier news article.

  • September 11, 2025

    Medicare Drug Pricing Plan Survives Novartis' 3rd Circ. Appeal

    The Third Circuit ruled Thursday that the Centers for Medicare & Medicaid Services' ability to negotiate "maximum fair prices" with drugmakers doesn't violate their constitutional rights, rejecting an argument by Novartis Pharmaceuticals Corp. that the practice amounted to a raw deal for the pharmaceutical industry.

  • September 11, 2025

    2 NY Fertility Clinics Must Face Suit Over Destroyed Eggs

    A New York federal judge on Thursday greenlit for trial a suit accusing two fertility clinics of negligently allowing a woman's eggs to be destroyed due to alleged mishandling, saying the claims can be considered ordinary negligence rather than medical malpractice.

  • September 11, 2025

    Industrial Tech Co. Sanctioned For Deleted Texts In Title VII Suit

    A New York federal judge has sanctioned ultrasonic testing company Sonotec after two of its staff members were found to have deleted text messages about a former employee who is pursuing sexual harassment retaliation claims against the company, finding they should have known litigation was imminent at the time they erased the correspondence.

  • September 11, 2025

    1st Circ. OKs Freeze Of Planned Parenthood Medicaid Funding

    The First Circuit on Thursday allowed the Trump administration to halt Medicaid reimbursements to Planned Parenthood and its affiliates, pausing a pair of lower court rulings that had blocked the funding cut.

  • September 11, 2025

    Ex-USPTO Solicitor Says Squires Is Better Than No One

    A former U.S. Patent and Trademark Office solicitor is asking the U.S. Senate to confirm John Squires as USPTO director, saying political accountability has become more important than finding a candidate who is right for the job.

  • September 11, 2025

    Insulin Makers Ask 2nd Circ. To Rethink Collusion Claims

    Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP are asking for a rehearing after a Second Circuit panel revived a proposed class action from safety-net hospitals and clinics accusing the companies of increasing insulin drug costs by agreeing to limit participation in a discount program.

  • September 11, 2025

    3rd Circ. Won't Toss Talc Co. Whittaker Clark & Daniels' Ch. 11

    Defunct talc supplier Whittaker Clark & Daniels properly filed for Chapter 11 protection in 2023 and its bankruptcy case should not be dismissed, the Third Circuit has ruled, siding against talc claimants who argued the company already being in receivership precluded it from filing for bankruptcy.

  • September 11, 2025

    7th Circ. Backs $183M FCA Award Over Eli Lilly Drug Rebates

    The Seventh Circuit refused on Thursday to unwind a whistleblower's $183 million trial win against Eli Lilly in a false claims case targeting more than a decade of drug rebate miscalculations, saying a jury reasonably found that the company knowingly "hid the truth" about how much it charged for Medicaid-covered drugs.

  • September 11, 2025

    Dental Supply Co.'s $84M Price-Fixing Deal Gets Final OK

    Dental supply company Dentsply Sirona Inc. and its investors have gotten final approval for an $84 million deal resolving consolidated shareholder class action claims that the company hurt investors by concealing a price-fixing scheme and a distributor's inventory buildup.

  • September 11, 2025

    Freshfields, Kirkland Advise On Advent's $4.7B Zentiva Sale

    European generics pharmaceutical company Zentiva will be sold by private equity firm Advent to U.S.-based GTCR, Advent announced Thursday.

  • September 11, 2025

    Zeiss Secures $785K In X-Ray Patent Trial Against Sigray

    Sigray Inc. is on the hook for $785,000 in damages after a finding in California federal court this week that it infringed X-ray imaging patents owned by Carl Zeiss X-Ray Microscopy Inc., but the jury also found that Sigray's infringement was not willful and refused to award any lost profits. 

  • September 11, 2025

    Cooley-Led LB Pharmaceuticals Raises Upsized $285M IPO

    LB Pharmaceuticals, a clinical-stage biopharma company developing therapies for a number of neuropsychiatric diseases, hit the public markets on Thursday after raising $285 million in an upsized initial public offering.

  • September 10, 2025

    Fed. Circ. Won't Revisit Double-Patenting, Soda TM Appeals

    The Federal Circuit on Wednesday declined to revisit its decisions in a trio of intellectual property cases, including one where it upheld an Acadia Pharmaceuticals Parkinson's disease drug patent and addressed double-patenting, and another deeming "Kist" and "Sunkist" soft drink marks confusingly similar.

  • September 10, 2025

    Teleradiology Co. Seeks OK Of Award Nixing $2M Fraud Claim

    An Indian teleradiology company asked a Georgia federal court not to vacate an arbitral award that rejected a radiology provider's $2 million fraud claim against it, arguing that the arbitrator properly interpreted their longstanding vendor–vendee contract.

  • September 10, 2025

    DexCom Beats Most Of Investors' Diabetes Device Sales Suit

    A California judge has trimmed a proposed class action from shareholders of glucose monitor manufacturer DexCom Inc. who allege they were damaged by the company's misrepresentations regarding its ability to keep up with growing demand, with the court determining the shareholders' complaint falls short in several instances.

  • September 10, 2025

    Hydroxycut Maker Iovate Gets Ch. 15 Relief As Case Kicks Off

    A New York bankruptcy judge agreed Wednesday to temporarily stay creditor actions against Canadian dietary supplement business Iovate Health Sciences one day after the Hydroxycut maker sought Chapter 15 protection.

Expert Analysis

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

  • Location Data And Online Tracking Trends To Watch

    Author Photo

    Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.

  • A Simple Way Courts Can Help Attys Avoid AI Hallucinations

    Author Photo

    As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors.

  • DOJ Consumer Branch's End Leaves FDA Litigation Questions

    Author Photo

    With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, companies must carefully monitor how responsibility is reallocated for civil and criminal enforcement cases related to products regulated by the U.S. Food and Drug Administration, say attorneys at Foley & Lardner.

  • The Evolving Legal Landscape For THC-Infused Beverages

    Author Photo

    A recent Eighth Circuit ruling, holding that states may restrict the sale of intoxicating hemp-derived products without violating federal law, combined with ongoing regulatory uncertainty at both the federal and state levels, could alter the trajectory of the THC-infused beverage market, say attorneys at Pashman Stein.

  • Series

    Creating Botanical Art Makes Me A Better Lawyer

    Author Photo

    Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning.

  • Opinion

    The Legal Education Status Quo Is No Longer Tenable

    Author Photo

    As underscored by the fallout from California’s February bar exam, legal education and licensure are tethered to outdated systems, and the industry must implement several key reforms to remain relevant and responsive to 21st century legal needs, says Matthew Nehmer at The Colleges of Law.

  • 2nd Circ. Reinforces Consensus On Vacating Foreign Awards

    Author Photo

    In Molecular Dynamics v. Spectrum Dynamics Medical, the Second Circuit recently affirmed that federal district courts do not possess subject matter jurisdiction to vacate foreign arbitral awards, strengthening this consensus across the circuits most active in recognition and enforcement actions, says Ed Mullins at Reed Smith.

  • E-Discovery Quarterly: Rulings On Relevance Redactions

    Author Photo

    In recent cases addressing redactions that parties sought to apply based on the relevance of information — as opposed to considerations of privilege — courts have generally limited a party’s ability to withhold nonresponsive or irrelevant material, providing a few lessons for discovery strategy, say attorneys at Sidley.

  • How DOJ's New Data Security Rules Leave HIPAA In The Dust

    Author Photo

    The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins.

  • Opinion

    Section 1983 Has Promise After End Of Nationwide Injunctions

    Author Photo

    After the U.S. Supreme Court recently struck down the practice of nationwide injunctions in Trump v. Casa, Section 1983 civil rights suits can provide a better pathway to hold the government accountable — but this will require reforms to qualified immunity, says Marc Levin at the Council on Criminal Justice.

  • Trump's 2nd Term Puts Merger Remedies Back On The Table

    Author Photo

    In contrast with the Biden administration, the second Trump administration has signaled a renewed willingness to resolve merger enforcement concerns through remedies from the outset, particularly when the proposed fix is structural, clearly addresses the harm and does not require burdensome oversight, say attorneys at Cooley.

  • Patent Ambiguity Persists After Justices Nix Eligibility Appeal

    Author Photo

    The Supreme Court recently declined to revisit the contentious framework governing patent eligibility by denying certiorari in Audio Evolution Diagnostics v. U.S., suggesting a necessary recalibration of both patent application and litigation strategies, say attorneys at Skadden.

  • Texas Med Spas Must Prepare For 2 New State Laws

    Author Photo

    Two new laws in Texas — regulating elective intravenous therapy and reforming healthcare noncompetes — mark a pivotal shift in the regulatory framework for medical spas in the state, which must proactively adapt their operations and contractual practices, says Brad Cook at Munsch Hardt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.